Co-founder and CTO


Dr. Martin Akerman is the Co-founder and CTO of Envisagenics. He is the inventor of the SpliceCore software platform, born out of his extensive research experience at the intersection of biology and data science and his vision of discovering RNA therapeutics using machine learning.

Martin trained as a post doctorate fellow with Dr. Adrian Krainer from Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology in 2009. As a first-time entrepreneur, Martin represented Envisagenics in winning the J&J AI for Drug Discovery QuickFire challenge in 2017 and Microsoft’s Innovate.AI challenge in 2018.

His goal is to combine cutting-edge computation with RNA domain expertise to develop innovative drugs for cancer and neurodegeneration.


DAY 1 / ‏‏‎ ‎

09:00 AM - 09:25 AM
Research & Discovery View Session

Using AI to Hit the Right Targets

Use Case: Discovery of splicing-based therapeutics with the SpliceCore platform

Martin Akerman, Co-founder and CTO, Envisagenics

Never miss an announcement

/* */